Uncategorised - Page 23

Tourette Syndrome Pipeline 2026: Investigational Therapies, Clinical Trial Advances, and Key Regulatory Developments by DelveInsight

According to DelveInsight’s latest evaluation, the global Tourette syndrome treatment pipeline features more than 6 prominent companies actively advancing over 6 investigational therapies. The comprehensive assessment covers ongoing clinical trials, therapeutic candidates, mechanisms of action, administration routes, and notable developmental milestones. The
25 March 2026

Hodgkin’s Lymphoma Market Poised for Strong Growth Through 2034, Driven by Innovative Therapies and Clinical Advancements | DelveInsight

DelveInsight’s “Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Hodgkin’s Lymphoma, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and
3 February 2026

Antisense Oligonucleotide Therapeutics Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2025” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers
2 February 2026

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Untreated Metastatic or Unresectable Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Untreated Metastatic or Unresectable Melanoma pipeline landscape. It covers the Untreated Metastatic or Unresectable Melanoma pipeline drug profiles, including clinical and
2 February 2026